CapsoVision (NASDAQ:CV) Upgraded by Roth Capital to Strong-Buy Rating

Roth Capital upgraded shares of CapsoVision (NASDAQ:CV) to a strong-buy rating in a report released on Tuesday,Zacks.com reports.

Other research analysts have also issued reports about the company. Weiss Ratings restated a “sell (e-)” rating on shares of CapsoVision in a research note on Wednesday, October 8th. Wall Street Zen raised CapsoVision to a “hold” rating in a report on Sunday, July 13th. Finally, Benchmark assumed coverage on CapsoVision in a report on Monday, July 28th. They issued a “speculative buy” rating and a $5.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $6.00.

CapsoVision Stock Performance

Shares of CapsoVision stock opened at $4.59 on Tuesday. CapsoVision has a 1 year low of $3.43 and a 1 year high of $5.72. The business has a fifty day moving average of $4.44.

CapsoVision (NASDAQ:CV) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($2.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($1.91). The business had revenue of $3.32 million for the quarter, compared to the consensus estimate of $3.20 million.

Institutional Trading of CapsoVision

A hedge fund recently bought a new stake in CapsoVision stock. New York State Common Retirement Fund acquired a new position in CapsoVision, Inc. (NASDAQ:CV) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 7,114 shares of the company’s stock, valued at approximately $34,000.

About CapsoVision

We are a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in our capsule endoscopy solutions to identify abnormalities of the gastrointestinal (“GI”) tract for diagnostic and screening purposes. We developed our first capsule endoscope system, currently comprising the CapsoCam Plus single-usecapsule and the CapsoCloud and CapsoView software, to panoramically visualize the small-bowel mucosa to investigate abnormalities such as obscure GI bleeding and Crohn’s disease.